Most importantly, BCL9-2 expression correlated with hormone receptor positivity of the cancers: Triple negative breast cancers showed no BCL9-2 overexpression, but BCL9-2 was elevated in Her2 positive tumors, confirming a previous study [58]. The gene discussed is NR4A1; the disease is breast carcinoma.